美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Aardvark Therapeutics

4.57

-2.1600-32.10%

盘前：4.52-0.0500-1.09%07:32 EDT

成交量：74.51万

成交额：351.61万

市值：9,915.48万

市盈率：-1.73

高：5.40

开：4.39

低：4.10

收：6.73

52周最高：17.94

52周最低：3.35

股本：2,169.69万

流通股本：588.80万

量比：4.91

换手率：12.65%

股息：- -

股息率：- -

每股收益(TTM):-2.6398

每股收益(LYR):-0.7400

净资产收益率：-58.79%

总资产收益率：-36.54%

市净率：1.14

市盈率(LYR):-6.18

数据加载中...

总览公司新闻资讯公告

热门话题-FDA对一种罕见病药物下达临床暂停令后，Aardvark股价重挫

FDA对Aardvark治疗普拉德-威利综合征极度饥饿药物下达全面临床暂停令

Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估，并确定该项目的后续计划

Aardvark Therapeutics 计划揭盲HERO与OLE研究数据，为FDA临床搁置后的前行之路提供指引

美国研究综述-亚马逊、Diamondback Energy、Matador Resources

Aardvark Therapeutics与Piper Sandler签订股权分销协议，于2026年3月23日提交SEC文件

Aardvark 在审查副作用时暂停两项肥胖症药物试验

Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验；最新指引预计2026年第二季度公布

Aardvark Therapeutics暂停Ard-201肥胖症项目，包括力量与体能试验；进一步指引预计2026年第二季度公布

BUZZ-券商观点：Aardvark 暂停后期试验后下滑；多位分析师下调 PT

美国研究综述-Aardvark Therapeutics、雪佛龙、Crowdstrike

RBC下调Aardvark Therapeutics评级至行业平配，目标价大幅砍至6美元

BUZZ-Aardvark Therapeutics 暂停晚期罕见病试验后下跌

Aardvark Therapeutics 暂停罕见病治疗后期试验

Aardvark Therapeutics：因超出目标剂量出现可逆性心脏观察结果，暂停Hero及开放标签扩展试验

Aardvark Therapeutics：基于超目标治疗剂量下可逆心脏观察结果作出决策

Aardvark Therapeutics 成立美国子公司推进皮肤病产品管线发展；任命 Bryan Jones 为首席执行官

Aardvark Therapeutics宣布向FDA提交并获IRB批准其主打候选药物ARD-101的修订试验方案，扩大普瑞德-威利综合征III期研究受试者资格

BUZZ--美国股票走势-Invivyd、美国天然气公司、新纪元能源公司

BUZZ-奥本海默将 Aardvark 评为 "跑赢大盘"，看好其差异化肥胖专营权

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AARD/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":4.57,"timestamp":1778875200000,"preClose":6.73,"halted":0,"volume":745088,"hourTrading":{"tag":"盘前","latestPrice":4.52,"preClose":4.57,"latestTime":"07:32 EDT","volume":1023,"amount":4385.789436599999,"timestamp":1779103932541,"change":-0.05,"changeRate":-0.010941,"amplitude":0.070372},"delay":0,"changeRate":-0.3209509658246657,"floatShares":5888000,"shares":21696893,"eps":-2.6398466,"marketStatus":"盘前交易","change":-2.16,"latestTime":"05-18 08:10:23 EDT","open":4.39,"high":5.4,"low":4.1,"amount":3516146.5690111998,"amplitude":0.193165,"askPrice":4.96,"askSize":100,"bidPrice":4.12,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.6398466,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":4.57,"preHourTrading":{"tag":"盘前","latestPrice":4.52,"preClose":4.57,"latestTime":"07:32 EDT","volume":1023,"amount":4385.789436599999,"timestamp":1779103932541,"change":-0.05,"changeRate":-0.010941,"amplitude":0.070372},"postHourTrading":{"tag":"盘后","latestPrice":4.57,"preClose":4.57,"latestTime":"19:58 EDT","volume":4099,"amount":18681.1516,"timestamp":1778889524203,"change":0,"changeRate":0,"amplitude":0.030635},"volumeRatio":4.914760661968818,"impliedVol":1.3464,"impliedVolPercentile":0.5875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-36.54%","roe":"-58.79%","lyrEps":-0.74,"volumeRatio":4.914760661968818,"shares":21696893,"dividePrice":0,"high":5.4,"amplitude":0.193165,"preClose":6.73,"low":4.1,"week52Low":3.35,"pbRate":"1.14","week52High":17.94,"institutionHeld":0,"latestPrice":4.57,"eps":-2.6398466,"divideRate":0,"volume":745088,"delay":0,"ttmEps":-2.6398466,"open":4.39,"prevYearClose":13.125,"prevWeekClose":4.57,"prevMonthClose":5.43,"prevQuarterClose":3.77,"fiveDayClose":5.44,"twentyDayClose":5.23,"sixtyDayClose":12.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-07","symbol":"AARD","fiscalQuarterEnding":"2026/03","expectedEps":-0.81,"name":null,"time":"盘前","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.99},{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"盘后","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"盘后","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"盘后","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-05-15","current":-1.731161,"percent":0.887821,"low":-51.17654,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"high":-1.329623,"avg":-9.137779,"sd":8.674072,"marketCap":146824271},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-08","current":-1.748556,"twenty":-10.125375,"median":-6.716536,"eighty":-4.705593,"marketCap":122169829},{"date":"2026-05-15","current":-2.101422,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"marketCap":146824271}],"updateTime":1779106223889},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635035232","title":"热门话题-FDA对一种罕见病药物下达临床暂停令后，Aardvark股价重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035232","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035232?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 23:48","pubTimestamp":1778860101,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL4S41S1FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635267467","title":"FDA对Aardvark治疗普拉德-威利综合征极度饥饿药物下达全面临床暂停令","url":"https://stock-news.laohu8.com/highlight/detail?id=2635267467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635267467?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 04:52","pubTimestamp":1778791934,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics周四表示，美国食品药品监督管理局已对其用于治疗与罕见疾病普拉德-威利综合征相关的极度饥饿症状的药物下达了全面临床暂停令，暂停了所有后期临床试验。此前在2月，Aardvark发现健康志愿者服用高于计划剂量的ARD-101药物后出现心脏相关副作用，因此 暂停了 患者招募和给药工作。FDA的临床暂停令适用于ARD-101的所有研究，包括针对普拉德-威利综合征的一项晚期临床试验及扩展研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4T41R20J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189600944","title":"Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估，并确定该项目的后续计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1189600944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189600944?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 04:03","pubTimestamp":1778789004,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc宣布，公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展（OLE）试验中的数据，以进行全面评估。此举旨在基于这些关键临床数据，为Ard-101项目的未来发展路径做出决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157105953","title":"Aardvark Therapeutics 计划揭盲HERO与OLE研究数据，为FDA临床搁置后的前行之路提供指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1157105953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157105953?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 04:03","pubTimestamp":1778788980,"startTime":"0","endTime":"0","summary":"在遭遇美国食品药品监督管理局（FDA）的临床搁置后，Aardvark Therapeutics 正计划揭盲其关键研究HERO与开放标签扩展（OLE）试验的数据。此举旨在深入分析现有数据，为确定公司未来的临床开发路径提供关键依据。通过审视这些未公开的详细结果，公司期望能更好地理解监管机构的关切，并据此制定出清晰、可行的后续策略，以推动其研发项目继续向前迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023948","title":"美国研究综述-亚马逊、Diamondback Energy、Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023948","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023948?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 16:02","pubTimestamp":1774425725,"startTime":"0","endTime":"0","summary":"美国研究综述-亚马逊、Diamondback Energy、Matador Resources路透3月25日 - 华尔街证券分析师周三调整了对亚马逊、Diamondback Energy 和 Matador Resources 等几家美国上市公司的评级和目标价。要闻  * 亚马逊AMZN.O：摩根大通将目标价从265美元上调至280美元 * Diamondback Energy Inc FANG.O：Gerdes Energy Research将评级从 \"买入 \"下调至 \"中性\"。* National Bank Holdings Corp NBHC.N：Piper Sandler开始覆盖并给予“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0098860793.USD","BK4598","LU2065171402.SGD","LU0109391861.USD","AMZZ","AMZY","HD","KHC","LU2473716301.USD","LU1236620834.HKD","AARD","LU2360032135.SGD","LU1235294995.USD","AZYY","MTDR","SGXZ51526630.SGD","MKC","IE00BJJMRX11.SGD","LU0251142724.SGD","LU0053666078.USD","LU0823434740.USD","LU1127390331.HKD","AMZN","EVGO","KBH","LU2756315318.SGD","BZAI","AMZD","LU2242649171.HKD","LU2381873111.SGD","LU0354030438.USD","AMZP","LU1868836757.USD","USAW.SI","FRPT","IE000KEQY171.SGD","LU0417517546.SGD","IE000YTNTUN2.SGD","AIR","BRZE","LENZ","LU0882574139.USD","VITL","AMZW","NBHC","AFG","FANG","AMZU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1132251302","title":"Aardvark Therapeutics与Piper Sandler签订股权分销协议，于2026年3月23日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251302","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132251302?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 18:11","pubTimestamp":1774347083,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. 已与Piper Sandler公司正式签署了一项股权分销协议。该协议的具体条款于2026年3月23日通过美国证券交易委员会（SEC）的文件对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621041087","title":"Aardvark 在审查副作用时暂停两项肥胖症药物试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621041087","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621041087?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302743,"startTime":"0","endTime":"0","summary":"路透3月23日 - Aardvark Therapeutics AARD.O周一表示，由于要审查其中一种药物的副作用，它已主动暂停了两项肥胖症试验性联合疗法的中期研究。ARD-201是Aardvark的实验药物ARD-101与默克公司的糖尿病药物MRK.N Januvia的组合。上个月，该公司在一项健康志愿者研究中对 ARD-101 进行安全监测时发现了与心脏有关的副作用。随后，该公司暂停了一项后期试验 ，即在患有罕见遗传性疾病普拉德-威利综合症的患者中测试 ARD-101。Aardvark公司表示，预计将在2026年第二季度提供有关这些药物的进一步更新信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4S40B1XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0353189763.USD","LU0965508806.USD","IE00B1BXHZ80.USD","LU0256863811.USD","IE00BFSS8Q28.SGD","LU2168564149.EUR","LU0471298777.SGD","LU1035775433.USD","LU1116320737.USD","LU2491050071.SGD","LU1868837300.USD","LU2271345857.HKD","SG9999001176.SGD","LU0882574139.USD","LU0316494557.USD","LU0114720955.EUR","LU1061106388.HKD","LU1127390331.HKD","LU1280957306.USD","LU0683600562.USD","LU1941712348.USD","LU2028103732.USD","LU1868836591.USD","IE00BFTCPJ56.SGD","LU2237443978.SGD","LU0417517546.SGD","LU0985320562.USD","LU0320765646.SGD","LU0094547139.USD","LU2357305700.SGD","LU2237443382.USD","SGXZ99366536.SGD","LU1037948897.HKD","LU2023250843.SGD","LU2462157665.USD","LU1989772923.USD","LU2089284900.SGD","LU1804176565.USD","LU2023251221.USD","LU0225283273.USD","LU1037948541.HKD","LU0265550359.USD","LU0266013472.USD","LU0965509283.SGD","LU0208291251.USD","LU2106854487.HKD","LU1551013425.SGD","IE00BLSP4452.SGD","IE00B4JS1V06.HKD","LU1934455863.HKD","LU2264538146.SGD","IE00BSNM7G36.USD","SGXZ81514606.USD","IE000M9KFDE8.USD","SG9999014559.SGD","IE00B1XK9C88.USD","LLYZ","LU0130517989.USD","BK4516","SG9999014542.SGD","SG9999014906.USD","LU0320765059.SGD","LU0471298694.HKD","LU1917777945.USD","LU0323591593.USD","LU0203201768.USD","IE00BFSS7M15.SGD","IE00BK4W5M84.HKD","LU0456855351.SGD","LU1551013342.USD","LU2750360997.AUD","IE00B775H168.HKD","LU0820562030.AUD","LU2108987350.USD","LU0882574055.USD","LU1585245621.USD","LU1291159041.SGD","LU0210536198.USD","LU0965509101.SGD","LU0689472784.USD","LU0354030511.USD","LU1069347547.HKD","LU1814569148.SGD","LU2471134796.USD","LU2112291526.USD","BK4550","SG9999015945.SGD","SG9999014880.SGD","SG9999014567.USD","ELIS","LU0823416689.USD","LU2468319806.SGD","SG9999015986.USD","BK4585","LU0106261372.USD","LU1069344957.HKD","IE00BLSP4239.USD","IE00BJJMRY28.SGD","IE00BWXC8680.SGD","LU2087625088.SGD","BK4581","BK4534","SG9999001176.USD","IE0002141913.USD","LU1548497426.USD","LU2237443465.HKD","GB00BDT5M118.USD","LU1145028129.USD","LU2168564495.EUR","LU1366192091.USD","BK4588","LU2324357040.USD","SG9999014914.USD","LU0096364046.USD","IE0004445239.USD","IE00BJJMRZ35.SGD","SG9999015358.SGD","LU1929549753.HKD","LU1162221912.USD","LU0353189680.USD","LU2491050154.USD","SG9999014898.SGD","IE00B2B36J28.USD","LU1201861249.SGD","LU2361045086.USD","LU1116320901.HKD","LU0477156953.USD","SGXZ31699556.SGD","LU2237438978.USD","LU0256863902.USD","AARD","IE00BN29S564.USD","LU2023250330.USD","SG9999017495.SGD","LU0006306889.USD","LU0079474960.USD","LU1232071149.USD","BK4599","LU1868837136.USD","LU1974910355.USD","LU1023059063.AUD","LU2211815571.USD","LU0868494708.USD","LU1629891620.HKD","IE00B4R5TH58.HKD","LU2265009873.SGD","LU0823434740.USD","IE00BJJMRX11.SGD","LU2360032135.SGD","SG9999015341.SGD","LU0122379950.USD","LU0211331839.USD","SG9999015978.USD","LU0786609619.USD","IE00BK4W5L77.USD","SG9999018857.SGD","LU0198837287.USD","LU0203202063.USD","LU0648001328.SGD","LU0289739699.SGD","LLYX","LU2602419157.SGD","LU1093756325.SGD","IE0005OL40V9.USD","LU2471134952.CNY","LU0889565916.HKD","IE0004445015.USD","BK4007","LU0708995401.HKD","LU1868836914.USD","LU2125154778.USD","LU2552382058.USD","BK4559","LLII","LU1868836757.USD","LU2168564222.USD","LU0238689110.USD","LU1989771016.USD","LU2361044865.SGD","LU0098860793.USD","LU2089984988.USD","LU2063271972.USD","LU1699723380.USD","LU0964807845.USD","LU1066051225.USD","LU1093756168.USD","LU2168564065.EUR","LU0466842654.USD","LU1934455194.USD","LU2552382132.HKD","LU0965509010.AUD","SGXZ51526630.SGD","IE00B7KXQ091.USD","LU2213496289.HKD","LU1934455277.USD","IE00BJT1NW94.SGD","LU2236285917.USD","LU0109391861.USD","IE0001KFT4U8.USD","LU1066053197.SGD","IE00BJLML261.HKD","LU2756315318.SGD","LU1323610961.USD","LU1720051108.HKD","LU1988902786.USD","IE00BN8TJ469.HKD","LU0354030438.USD","LU2237443622.USD","LU1066051498.USD","LU2417539215.USD","LU2491049909.HKD","LU1057294990.SGD","IE0009355771.USD","LU2552382215.SGD","LU1066051811.HKD","LU0061475181.USD","LU0130102774.USD","LU0058720904.USD","LU0943347566.SGD","LU2168563687.JPY","LU2750360641.GBP","SG9999002224.SGD","SGXZ57979304.SGD","SG9999018865.SGD","LU0385154629.USD","LU0820561909.HKD","LU1064131342.USD","LU0265550946.USD","LU2746668461.USD","IE00BKDWB100.SGD","LU0861579265.USD","LU1941712264.USD","LU2125154935.USD","LU1623119135.USD","LU2456880835.USD","LU0097036916.USD","LU1720051017.SGD","LU0820561818.USD","LU0640476718.USD","LU2461242641.AUD","LU2089283258.USD","IE00BKPKM429.USD","LU2023250504.SGD","SG9999015952.SGD","LU0203345920.USD","LU0320765992.SGD","LU0158827781.USD","LU0203347892.USD","LU0109394709.USD","IE00BBT3K403.USD","LU0432979614.USD","LU0672654240.SGD","LU0070302665.USD","LU2896262040.SGD","LU0942090050.USD","LU2746668974.SGD","LU1035773651.USD","LU2237443549.SGD","LU2471134879.HKD","LU2360106947.USD","SG9999002232.USD","SG9999014575.USD","LU0158827948.USD","SG9999013999.USD","LU0980610538.SGD","LU1571399168.USD","ELIL","LU2361044949.HKD","LU1712237335.SGD","LU0320765489.SGD","LU2111349929.HKD","LU1267930730.SGD","LU0868494617.USD","LU2471134523.USD","LU1983299246.USD","LU2756315664.SGD","LU2237443895.HKD","SG9999001440.SGD","BK4533","LU0787776722.HKD","LU0234572021.USD","LU0823434583.USD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815608","title":"Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验；最新指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146815608?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 04:23","pubTimestamp":1774297410,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征（PWS）的三期HERO临床试验及开放标签扩展（OLE）研究。\n公司表示，预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125745058","title":"Aardvark Therapeutics暂停Ard-201肥胖症项目，包括力量与体能试验；进一步指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1125745058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125745058?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 04:21","pubTimestamp":1774297278,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics已决定暂停其Ard-201肥胖症治疗项目的研发进程，该项目原计划包含针对患者力量与体能改善的临床试验。公司表示，关于该项目的后续发展方向及详细计划，预计将在2026年第二季度提供进一步的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337005","title":"BUZZ-券商观点：Aardvark 暂停后期试验后下滑；多位分析师下调 PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337005","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337005?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 21:33","pubTimestamp":1772458409,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：Aardvark 暂停后期试验后下滑；多位分析师下调 PT路透3月2日 - ** Aardvark Therapeutics AARD.O周五主动暂停了一项晚期试验，测试其对一种罕见遗传病的实验性治疗，因为在健康志愿者身上发现了与心脏有关的副作用。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4S3ZQ1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616385122","title":"美国研究综述-Aardvark Therapeutics、雪佛龙、Crowdstrike","url":"https://stock-news.laohu8.com/highlight/detail?id=2616385122","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616385122?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 15:29","pubTimestamp":1772436594,"startTime":"0","endTime":"0","summary":"美国研究综述-Aardvark Therapeutics、雪佛龙、Crowdstrike路透3月2日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括Aardvark Therapeutics、雪佛龙和Crowdstrike。* Aardvark Therapeutics Inc AARD.O：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。* Aardvark Therapeutics Inc AARD.O：加拿大皇家银行将目标价从18美元下调至6美元 * ACM Research Inc ACMR.O：摩根大通将目标价从45美元上调至70美元 * AES Corp AES.N：Seaport Research Partners将其评级从 \"卖出 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4T3ZQ0JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","CVX","IE00BN8TJ469.HKD","MSDL","COP","LU2460026573.USD","FSLY","LU2764263203.CNY","RRC","SITC","AARD","CRWD","LU0466842654.USD","LU2211815571.USD","LU2756315318.SGD","AVL","FLUT","LU2065171402.SGD","LU1201861165.SGD","TTDU","LU2322448791.USD","LU0949170772.SGD","AES","SG9999015978.USD","AVGX","BOBS","LU0225283273.USD","AVGW","XOMZ","LU1670710588.SGD","MTZ","BK4129","LU1066053197.SGD","CRWL","LU2462611646.USD","BK4560","AVGU","ACMR","QSR","AVS","AVGG","IE00BKDWB100.SGD","XOMX","NMRK","FPS","XOMO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1103365650","title":"RBC下调Aardvark Therapeutics评级至行业平配，目标价大幅砍至6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103365650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103365650?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 13:52","pubTimestamp":1772430778,"startTime":"0","endTime":"0","summary":"加拿大皇家银行（RBC）宣布，将Aardvark Therapeutics的股票评级从“跑赢大盘”下调至“行业平配”，同时将其目标价从18美元大幅削减至6美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614602638","title":"BUZZ-Aardvark Therapeutics 暂停晚期罕见病试验后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614602638","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614602638?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 06:13","pubTimestamp":1772230395,"startTime":"0","endTime":"0","summary":"2月27日 - ** 药物开发商Aardvark Therapeutics AARD.O股价盘后下跌47.2%至6.58美元 ** 该公司表示，它将自愿暂停  其晚期试验，测试其治疗一种罕见遗传病的实验性疗法。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4S3ZN24Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614862450","title":"Aardvark Therapeutics 暂停罕见病治疗后期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862450","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862450?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 05:11","pubTimestamp":1772226675,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 暂停罕见病治疗后期试验路透2月27日 - Aardvark Therapeutics公司AARD.O周五表示，该公司将自愿暂停其针对一种罕见遗传病的实验性治疗的后期试验。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4T3ZN20S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162306225","title":"Aardvark Therapeutics：因超出目标剂量出现可逆性心脏观察结果，暂停Hero及开放标签扩展试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162306225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162306225?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 05:08","pubTimestamp":1772226491,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布，在发现高于目标剂量出现可逆性心脏相关观察结果后，已决定暂停其Hero试验以及开放标签扩展研究。公司强调，该心脏异常现象在停药后具有可逆性，目前正与监管机构密切沟通，进一步评估相关数据以确定后续研究方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177858931","title":"Aardvark Therapeutics：基于超目标治疗剂量下可逆心脏观察结果作出决策","url":"https://stock-news.laohu8.com/highlight/detail?id=1177858931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177858931?lang=zh_cn&edition=fundamental","pubTime":"2026-02-28 05:08","pubTimestamp":1772226490,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，其决策依据是在高于目标治疗剂量下发现的可逆性心脏观察结果。这一发现对药物安全性评估具有关键意义，表明在特定剂量范围内出现的心脏影响是可逆的，为公司后续临床开发路径提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174773215","title":"Aardvark Therapeutics 成立美国子公司 推进皮肤病产品管线发展；任命 Bryan Jones 为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1174773215","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174773215?lang=zh_cn&edition=fundamental","pubTime":"2026-02-12 21:06","pubTimestamp":1770901613,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 宣布成立新的美国子公司，旨在支持其皮肤病产品管线的开发进程。公司同时宣布，任命 Bryan Jones 担任该子公司的首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193243066","title":"Aardvark Therapeutics宣布向FDA提交并获IRB批准其主打候选药物ARD-101的修订试验方案，扩大普瑞德-威利综合征III期研究受试者资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193243066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193243066?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 21:05","pubTimestamp":1770728724,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593473411","title":"BUZZ--美国股票走势-Invivyd、美国天然气公司、新纪元能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593473411","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593473411?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 00:20","pubTimestamp":1766506822,"startTime":"0","endTime":"0","summary":"标普500指数.SPX上涨0.04%，报6881.36点；纳斯达克综合指数.IXIC下跌0.02%，报23425.18点。nL4N3XT0LJ ** Invivyd Inc IVVD.O:BUZZ - 因制药商开始COVID预防抗体的后期试验而上涨。nL4N3XT0M7 ** Freeport-McMoRan Inc FCX.N:BUZZ - 富国银行上调 Freeport-McMoRan PT，因铜业前景光明；股价上涨 nL6N3XT0JK ** Aardvark Therapeutics Inc AARD.O:BUZZ - 奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRDY","HII","LU1992135472.HKD","AARD","HIHO","NOW","HL","SOS","LU0081259029.USD","CDE","LU2458330169.SGD","AFJK","IE00B19Z9P08.USD","BK4127","LU0154245673.USD","RVPH","PCLA","LU1223083913.SGD","LU0314106906.USD","BK4141","IVVD","HXHX","CNX","GILD","LU0094547139.USD","SGXZ81514606.USD","NUAI","IE00B1XK9C88.USD","NINE","LU2168564495.EUR","AME","SG9999015952.SGD","FCX","BK4139","LU0654597011.USD","FSLR","LU2211815571.USD","NEM","EQT","AZO","EXE","LU0158827948.USD","SOC","SPRB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2593349790","title":"BUZZ-奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349790","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593349790?lang=zh_cn&edition=fundamental","pubTime":"2025-12-23 20:25","pubTimestamp":1766492743,"startTime":"0","endTime":"0","summary":"BUZZ-奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权12月23日 - ** 券商奥本海默给予Aardvark Therapeutics AARD.O\"跑赢大盘 \"评级和35美元的目标价，这意味着该股较上一交易日收盘价有超过两倍的上涨空间。** 奥本海默认为，AARD公司即将推出的治疗PWS的实验性药物ARD-101的后期研究结果是一个重要催化剂，并认为与Soleno Therapeutics公司SLNO.O获得FDA批准的药物Vykat XR相比，ARD-101可能具有更好的安全性。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","AARD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}